Stockscreener 앱 받기
4.8071
3.41%
-0.1729
전일 마감가:
$4.98
열려 있는:
$4.89
하루 거래량:
533.04K
Relative Volume:
0.38
시가총액:
$414.87M
수익:
$20.65M
순이익/손실:
$-192.65M
주가수익비율:
-1.5164
EPS:
-3.17
순현금흐름:
$-134.39M
1주 성능:
-4.18%
1개월 성능:
-28.21%
6개월 성능:
-63.78%
1년 성능:
-63.73%
1일 변동 폭
$4.80
$5.09
1주일 범위
$4.76
$5.11
52주 변동 폭
$4.305
$20.12
Verve Therapeutics Inc Stock (VERV) Company Profile
명칭
Verve Therapeutics Inc
전화
(978) 501-3026
주소
201 BROOKLINE AVENUE, BOSTON
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-10-06 | 개시 | Credit Suisse | Neutral |
| 2022-08-25 | 업그레이드 | Stifel | Hold → Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-07-12 | 개시 | Guggenheim | Buy |
| 2021-07-12 | 개시 | JP Morgan | Neutral |
| 2021-07-12 | 개시 | Jefferies | Buy |
| 2021-07-12 | 개시 | William Blair | Outperform |
모두보기
Verve Therapeutics Inc 주식(VERV)의 최신 뉴스
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: - GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve - The Bakersfield Californian
Analyzing Ratios: Verve Therapeutics Inc (VERV)’s Financial Story Unveiled - The Dwinnex
Verve Therapeutics Inc (VERV)’s stock price range in the last year - US Post News
7 Best NASDAQ Stocks Under $5 - Insider Monkey
ROSEN, A LEADING NATIONAL FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel - The Bakersfield Californian
ROSEN, A LEADING NATIONAL FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - GlobeNewswire Inc.
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Shareholders that lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - PR Newswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
VERV Stock Sees Decline of Approximately -13.43% in Last Five Days - Knox Daily
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - Lelezard
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - GlobeNewswire Inc.
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - Morningstar
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - Daily Guardian Canada
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - GlobeNewswire
Verve Therapeutics Inc (VERV) is looking forward to a strong quarter - SETE News
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - PR Newswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - PR Newswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - Stockhouse Publishing
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Was there any good news for Verve Therapeutics Inc (VERV) stock in the last session? - US Post News
Levi & Korsinsky Notifies Shareholders of Verve Therapeutics, Inc.(VERV) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - Stockhouse Publishing
Investing in Verve Therapeutics Inc (VERV) Is Getting More Attractive - Knox Daily
Ratios in Focus: Analyzing Verve Therapeutics Inc (VERV)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Reminds Verve Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - PR Newswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline - ForexTV.com
2024-09-22 | SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics | NDAQ:VERV | Press Release - Stockhouse Publishing
DekaBank Deutsche Girozentrale Sells 2,690 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Verve - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - GlobeNewswire Inc.
Jim Cramer on Vertiv Holdings (VRT): ‘I Think It’s A Winner’ - Yahoo Finance
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
VERV’s Stochastic Averages Dip: Analyzing Verve Therapeutics Inc’s Stock Performance - The InvestChronicle
Jim Cramer on Verve Therapeutics Inc. (VERV): ‘I Think It’s A Winner’ - Insider Monkey
Insider Buying: Ashe Andrew D., Verve Therapeutics Inc [VERV] insider invested 76,000 shares - Knox Daily
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - GlobeNewswire
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics LawsuitVERV - PR Newswire
Verve Therapeutics, Inc. (NASDAQ:VERV) Position Trimmed by Federated Hermes Inc. - MarketBeat
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – VERV - MSN
Views of Wall Street’s Leading Experts on Verve Therapeutics Inc - SETE News
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – VERV - ForexTV.com
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Daiwa Securities Group Inc. - Defense World
Shareholders that lost money on Verve Therapeutics, Inc.(VERV) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - Invezz
VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit - ForexTV.com
VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders - GlobeNewswire
Verve Therapeutics Inc (VERV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verve Therapeutics Inc 주식 (VERV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ashe Andrew D. | See Remarks |
May 14 '24 |
Buy |
6.26 |
76,000 |
475,760 |
342,509 |
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '24 |
Sale |
8.24 |
1,514 |
12,475 |
8,659 |
| Dorval Allison | Chief Financial Officer |
Nov 29 '23 |
Sale |
11.45 |
554 |
6,343 |
4,060 |
0.39%
2.64%
자본화:
|
볼륨(24시간):